Aignostics Raises €14 Million in Series A  

by Kay Aloha Villamor in September 15th, 2022

Aignostics, a spin-off from Charité – Universitätsmedizin Berlin, developing novel digital pathology solutions with “Explainable AI” for pharmaceutical research and diagnostics, today announced the closing of an oversubscribed €14 million in Series A funding.

The round was led by Wellington Partners, joined by existing investors Boehringer Ingelheim Venture Fund (BIVF), VC Fonds Technologie managed by IBB Ventures and High-Tech Gründerfonds (HTGF). CARMA Fund, initiated by Ascenion, also participated as a new investor.

The funds will be used to expand the U.S market presence and further advance the AI platform. To date, Aignostics has raised close to €20 million in funding.

“With this new round of funding, we want to continue building our presence and team. In particular, we will put a stronger focus on the US market, in which we have been active since the beginning of this year,” explained Viktor Matyas, CEO, and co-founder of Aignostics. “By accelerating our investments into our platform and regulatory excellence, we will be able to offer a Good Clinical Practice (GCP) compliant development and analysis process starting in early 2023, and we plan to have first AI models in use in early-stage clinical trials soon thereafter. Eventually, we aim to become a credible choice for global Companion Diagnostic (CDx) developments too.”

Company: AIgnostics GmbH

Raised: €14.0M

Round: Series A

Funding Month: September 2022

Lead Investors: Wellington Partners

Additional Investors: Boehringer Ingelheim Venture Fund (BIVF), VC Fonds Technologie, High-Tech Gründerfonds (HTGF), and CARMA Fund

Company Website:

Software Category: AI-powered pathology

About the Company: Aignostics specializes in AI-powered pathology, uniquely combining proprietary technology, its pathologist network, and access to key data modalities to build bespoke AI models for its global pharma and biotech client base. These AI models can deliver valuable insights into disease biology from tissue samples, such as novel biomarkers and drug response characteristics.

Aignostics formally started in 2018 in the Digital Health Accelerator program of the Berlin Institute of Health (BIH), based on joint research by Charité – Universitätsmedizin Berlin, one of Europe’s largest university hospitals, led by Prof. Frederick Klauschen, and TU Berlin, led by Prof. Klaus-Robert Müller. In early 2020, Aignostics was spun-out of Charité and has offices in Berlin, Germany, and Boston, U.S.


Your cart